Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Average (2016 - 2025)

Historic Equity Average for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $888.1 million.

  • Catalyst Pharmaceuticals' Equity Average rose 3990.84% to $888.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $888.1 million, marking a year-over-year increase of 3990.84%. This contributed to the annual value of $557.8 million for FY2024, which is 6206.74% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Equity Average stood at $888.1 million for Q3 2025, which was up 3990.84% from $825.2 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Equity Average high stood at $888.1 million for Q3 2025, and its period low was $174.1 million during Q1 2021.
  • For the 5-year period, Catalyst Pharmaceuticals' Equity Average averaged around $421.3 million, with its median value being $354.5 million (2023).
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Equity Average soared by 2262.83% in 2022, and later surged by 8855.49% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Equity Average stood at $202.7 million in 2021, then surged by 40.68% to $285.2 million in 2022, then rose by 29.09% to $368.2 million in 2023, then skyrocketed by 88.55% to $694.3 million in 2024, then increased by 27.92% to $888.1 million in 2025.
  • Its Equity Average was $888.1 million in Q3 2025, compared to $825.2 million in Q2 2025 and $761.0 million in Q1 2025.